Vinay Prasad
vinay prasad questions whether medicine's consensus got the evidence right, then says it loudly
Vinay Kashyap Prasad is an American hematologist-oncologist and health researcher, who served as the director of the Center for Biologics Evaluation and Research from May 2025 to April 2026 at the Food and Drug Administration (FDA). He is a professor of epidemiology and biostatistics at the University of California,… wikipedia →
12-month trajectory
recent news
prasad's departure announcement
- Vaccine Chief to Leave F.D.A. - The New York Times
- Vinay Prasad to exit CBER as FDA group director - European Pharmaceutical Review
- Vinay Prasad to leave the FDA again - Clinical Trials Arena
+ 16 more
prasad's misconduct and controversy
- Vinay Prasad: Anthony Fauci’s Vaccine Deceptions - The Free Press
- FDA disavows Makary, Prasad’s papers as lawmaker blasts ‘shoot-from-the-hip’ policymaking - BioSpace
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now) - The Cancer Letter
+ 6 more
fda leadership transition
- Under a new leader, the FDA’s biologics center moves to steady itself after stormy chapter - STAT
- Katherine Szarama steps in as CBER acting director, replacing Prasad - The Cancer Letter
- UPDATED—Trump plans to fire FDA chief Marty Makary: report - Fierce Pharma
+ 9 more
industry impact and biotech response
- UniQure to file gene therapy for approval, reflecting major shifts at FDA - BioPharma Dive
- Opinion: Prasad’s FDA exit good for rare diseases but new CBER head must repair eroded trust - BioSpace
- Opinion: FDA delays on rare disease drugs put my son and other children with rare diseases at risk - El Paso Matters
+ 8 more